Humacyte, Inc. — Director's Dealing 2025

Dec 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2021-08-26

Reporting Person: FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ (Former 10% Shareholder)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001 per share	18312735	Direct

Footnotes

F1: Excludes the Reporting Person's pro rata share of up to 15,000,000 additional shares of the Issuer's Common Stock which may become issuable to the former shareholders of Humacyte, Inc. pursuant to the terms of the Business Combination Agreement dated as of February 17, 2021 by and among the Issuer, Hunter Merger Sub, Inc. and Humacyte, Inc., as to which the Reporting Person disclaims any present beneficial ownership interest.

F2: This Form 4 is being filed solely to report that the Reporting Person is no longer subject to Section 16. (See the checkbox on page 1.) The decrease in the Reporting Person's beneficial ownership to less than 10% is solely the result of an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of the Reporting Person's Initial Statement of Beneficial Ownership on Form 3. Neither of the Reporting Person nor FME (see note 3) has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of such Form 3 on September 2, 2021.

F3: Fresenius Medical Care Holdings, Inc. is an indirect, wholly-owned subsidiary of Fresenius Medical Care AG ("FME"). FME's address is Else-Kroner Strasse 1, 61352 Bad Homburg, Germany.